RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
@ISMPOofficial
So relevant to our practice.
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
RT @drkpavithran: EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, es…
EGFR mutant lung adenocrcinoma patients with concomitant Pulmonary tuberculosis respond poorly to EGFR-TKI treatment, especially in terms of survival outcome https://t.co/hFdmw1eDfk https://t.co/xCRDpYPXgn